Amarantus Bioscience Holdings Inc (AMBS)

[MagicCap]

By the way, the 90% homology issue that was held up in court might suggest that any alteration of GDNF and CDNF and Neurturin could infringe on AMBS's patents of MANF. These proteins are all similar in some sense yet MANF has been shown to be much more successful than GDNF, and researchers might feel compelled to alter GDNF in a way that it becomes more like MANF and the 90% homology factor (i.e., if anything has a 90% similarity to MANF) could cause researchers to have to come to AMBS to get a license to work on it.

When you get a chance read this article closer:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s

I think this part is very important:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."

I would not take this issue lightly. I think it is what makes this protein so valuable and why I think a market cap of $30 MIllion is laughable.

FD: I have been long since $0.03 all the way down to $0.018. My average is around $0.025 or so. However, I think this should be worth at least $100 Million right now. That would be based on a significant discount to the purchase price of GDNF at the same stage of testing that MANF is in (i.e., pre clinical) and what was spent so far on Neurturin. I think there is a potential that we could see AMBS climb to $1.00, though, especially if the bull market in biotech stocks continues which I see no reason why it won't.